Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459934 | 0.87 | CA12 (0.44) | MAOBNPC1RAB9AAPPMAPT | |
| SCHEMBL5322041 | 0.86 | MAOB (0.42) | MAOBNPC1RAB9AAPPNFE2L2 | |
| SCHEMBL5622659 | 0.84 | ACHE (0.45) | MAOBNPC1RAB9AMAPTMEN1 | |
| SCHEMBL16719334 | 0.83 | NFE2L2 (0.46) | MAOBNPC1RAB9ANFE2L2MAPK14 | |
| SCHEMBL3262111 | 0.82 | ESR2 (0.52) | NPC1RAB9AAPPNQO2MAPT | |
| SCHEMBL11205461 | 0.82 | APP (0.39) | MAOBNPC1RAB9AAPPMAPK14 | |
| SCHEMBL10918406 | 0.82 | CYP11B1 (0.44) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4468568 | 0.82 | MEN1 (0.40) | MAOBRAB9AMAPTTP53MEN1 | |
| SCHEMBL6841236 | 0.82 | MEN1 (0.38) | NPC1RAB9AMAPTMEN1ALOX15 | |
| SCHEMBL7033071 | 0.81 | CA4 (0.43) | NPC1RAB9AMAPTTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023709-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2019-01-24 | — | — | US | disclosed |
| US-10100056-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-10-16 | — | — | US | disclosed |
| US-20170253596-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | TARO PHARMACEUTICALS INC. (CA) | 2017-09-07 | — | — | US | disclosed |
| US-20160083387-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-03-24 | — | — | US | disclosed |
| EP-2970100-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| EP-2780326-A1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | Vivolux Ab (SE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014143561-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013058691-A1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | VIVOLUX AB (SE) | 2013-04-25 | — | — | WO | disclosed |
| CN-1751039-A | Pyridine derivatives as fungicidal compounds | BAYER CROPSCIENCE SA (FR) | 2006-03-22 | — | — | CN | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5134150-A | Administering diaryl-substituted imidazothiazoles; antiarthritic agents | SMITHKLINE BEECHAM CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| US-5120848-A | Anticholesterol and antilipemic agents; hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitors | GLAXO GROUP LIMITED (GB) | 1992-06-09 | — | — | US | disclosed |
| US-5013749-A | Imidazole derivatives and their use as hypercholesterolemia and hyperlipoproteinemia agents | GLAXO GROUP LIMITED (GB) | 1991-05-07 | — | — | US | disclosed |
| US-4808607-A | ATHEROSCLEROSIS, HYPERLIPOPROTEINEMIA | SANDOZ PHARM. CORP. (US) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023709-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | MAOB 2459/4885NPC1 1207/4885RAB9A 806/4885 |
| US-20160083387-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | MAOB 2459/4885NPC1 1207/4885RAB9A 806/4885 |
| US-20170253596-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PPP1R1B, PPM1A | MAOB 2459/4885NPC1 1207/4885RAB9A 806/4885 |
| US-10100056-B2 | SHIP1 modulators and methods related thereto | PPM1D, PPP1R1B, PPM1A | MAOB 2459/4885NPC1 1207/4885RAB9A 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.